- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01997359
Multi-level Determinants of Starting ART Late: Aim 3 (LSTART)
Multi-level Determinants of Starting ART Late in Sub-Saharan Africa (LSTART Study): A Case-control Study to Identify Individual-level Risk Factors for Late ART Initiation in Ethiopia
The availability of HIV care and treatment programs is increasing in sub-Saharan Africa. However more than half the patients who need HIV treatment are still not receiving antiretroviral therapy (ART). This can lead to early death from AIDS. Additionally, many patients start ART late after the HIV disease is very advanced. This results in high death rates soon after starting ART. The factors that contribute to late ART initiation are still unclear. This study will identify factors that help patients to enroll or prevent them from enrolling into HIV care and starting ART on time. We will examine the characteristics of all patients initiating ART at study sites. We will also look at potential risk factors among patients who initiate ART late (cases) compared to patients who initiate earlier (controls) at 6 HIV care and treatment clinics in Ethiopia. Data will be collected using 2 methods:
- Face-to-face interviews with participants using questionnaires
- Obtaining clinical data from the electronic patient-level database
Identifying factors that help patients to start or prevent them from starting ART on time will help to direct interventions, programs and policies to reduce early death.
Panoramica dello studio
Stato
Descrizione dettagliata
Background: Although HIV care and treatment programs are being scaled up in sub-Saharan Africa, more than 50% of the patients in need of ART are not receiving it and there is still significant mortality from AIDS. One of the major challenges is high rates of late ART initiation (i.e., in the advanced stages of HIV disease) which results in high rates of mortality soon after initiation of ART. The individual-level factors that contribute to late ART initiation are still unclear. Objective: As the 3rd part of a 3-phase NIH-sponsored project, this study aims to identify individual-level enablers and barriers to timely enrollment into HIV care and ART initiation.
Methods: We will be recruiting all patients newly initiating ART at the study sites for descriptive analysis (approximately 1,200). As a sub-analysis, we will be utilizing a case-control approach to examine potential individual risk factors (e.g. knowledge and behaviors around HIV care and treatment, experience of stigma, and other perceived barriers and enablers to earlier HIV diagnosis, enrollment into care, and ART initiation) among 360 patients who initiated ART late (CD4 count <150 cells/µL compared to 360 patients who initiated earlier (CD4≥200) at 6 HIV care and treatment clinics in Ethiopia. For both the descriptive study and case-control study, data will be collected using 2 methods:
- Face-to-face interviews with participants using structured questionnaires
- Abstraction of clinical data from the electronic patient-level database to capture patient information at baseline, 6 and 12 months after enrollment in the study
Expected use of results: Identifying individual-level enablers and barriers of timely ART initiation will facilitate implementation of interventions, programs and policies to mitigate the problem of late ART initiation.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Ambo, Etiopia
- Ambo Hospital
-
Bishoftu, Etiopia
- Bishoftu hospital
-
Fitche, Etiopia
- Fitche Hospital
-
Goba, Etiopia
- Goba Hospital
-
Nekemte, Etiopia
- Nekemte Hospital
-
Shashamene, Etiopia
- Shashamene Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Aged 18 years (the age of majority in Ethiopia) or older.
- ART naïve.
- Eligible for ART according to Ethiopia's National ART guideline criteria.
- Have received a prescription for ART during the study period.
- Speak either Oromiffa or Amharic.
Special inclusion criteria for case-control sub-analysis:
- Cases: CD4 count <150 cells/µL (regardless of WHO stage)
- Controls: CD4 ≥200.
Exclusion Criteria:
- Overtly cognitively impaired
- Inability or unwillingness to provide informed consent
- Actively incarcerated
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Key Informant Interviews
Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
|
Prospective Cohort
The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients.
Cases will be adults initiating ART with either: CD4 count <150 cells/µL.
Controls will be adults who initiate ART with CD4≥200 .
Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups.
We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Proportion of Persons Initiating ART Late
Lasso di tempo: 12 months
|
12 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Batya Elul, PhD, MSc, ICAP-NY, Columbia University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Malattie del sistema immunitario
- Malattie da virus lenti
- Infezioni da HIV
- Sindrome da immunodeficienza acquisita
- Sindromi da deficit immunologico
Altri numeri di identificazione dello studio
- AAAI1960
- 1R01MH089831 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Virus dell'immunodeficienza umana (HIV)
-
RTI InternationalCenters for Disease Control and PreventionCompletatoVirus dell'immunodeficienza umana (HIV) PositivoStati Uniti
-
AbbVieCompletatoInfezione da HIV | HIV-1 | Virus dell'immunodeficienza umana (HIV)Stati Uniti, Australia, Canada, Porto Rico
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development... e altri collaboratoriCompletatoProfilassi del virus dell'immunodeficienza umana (HIV).Stati Uniti
-
University of MiamiCompletato
-
University of AarhusAarhus University HospitalCompletatoHIV | Virus del papilloma umanoDanimarca
-
Janssen-Cilag International NVCompletatoInfezioni da virus dell'immunodeficienza umana (HIV). | Virus della sindrome da immunodeficienza acquisita (AIDS).Francia, Regno Unito, Belgio, Germania, Spagna, Svizzera, Danimarca, Israele, Austria, Polonia, Ungheria, Svezia, Irlanda
-
Energex Systems, Inc.SconosciutoInfezioni da HIV | HIVStati Uniti
-
Gilead SciencesCompletatoHIV | Virus dell'immunodeficienza umana | HIV-1Stati Uniti, Porto Rico
-
Merck Sharp & Dohme LLCRitiratoInfezioni da virus dell'immunodeficienza umana (HIV).
-
Bristol-Myers SquibbCompletatoInfezioni da virus dell'immunodeficienza umana (HIV).Spagna